A hub-and-spoke model to deliver effective access to chimeric antigen receptor T-cell therapy in a public health network: the Catalan Blood and Tissue Bank experience-Reference-Cited by-同舟云学术

A hub-and-spoke model to deliver effective access to chimeric antigen receptor T-cell therapy in a public health network: the Catalan Blood and Tissue Bank experience

Published:2023-01 Issue:1 Volume:25 Page:14-19
ISSN:1465-3249
Container-title:Cytotherapy
language:en
Short-container-title:Cytotherapy

Author:

Fernandez-Sojo Jesus^ORCID,Delgadillo Joaquim^ORCID,Vives Joaquim^ORCID,Rodriguez Luciano,Mendoza Ana,Azqueta Carmen,Garcia-Buendia Ana,Valdivia Elena,Martorell Lluis,Rubio-Lopez Nuria,Linares Mónica^ORCID,Alonso Sofia,Ancochea Agueda,García-Rey Enric,García-Muñoz Nadia,Medina Laura,Querol Sergio

Publisher

Elsevier BV

Subject

Cancer Research,Transplantation,Cell Biology,Genetics (clinical),Oncology,Immunology,Immunology and Allergy

Reference21 articles.

1. Chimeric antigen receptor therapy for B-cell malignancies;Porter;J Cancer,2011

2. U.S. Food & Drug Administrations (FDA). KYMRIAH (tisagenlecleucel). 2020. Available online: www.fda.gov/vaccines-blood-biologics/cellular-genetherapy-products/kymriah-tisagenlecleucel (accessed April 2022).

3. U.S. Food & Drug Administrations (FDA). Yescarta (axicabtagene ciloleucel). 2020. Available online: www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel (accessed April 2022).

4. Pharmaceutical Technology. Novartis receives EC approval for Kymriah to treat two cancers. 2018. Available online: www.pharmaceutical-technology.com/news/novartis-european-commissions-approval-kymriah/#:∼:text=The%20European%20Commission%20(EC)%20has,%2Dcell%20lymphoma%20(DLBCL) (accessed April 2022).

5. European Medicines Agency (EMA). Yescarta. 2020. Available online: www.ema.europa.eu/en/medicines/human/EPAR/yescarta (accessed April 2022)

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The expanding role of blood and tissue establishments in the development of advanced therapy medicinal products;Cytotherapy;2024-05

2. Piloting delivery of PfSPZ vaccines for malaria through a cryogenic vaccine cold chain to travel and military medicine clinics;Journal of Travel Medicine;2024-01-11

3. A management model in blood, tissue and cell establishments to ensure rapid and sustainable patient access to advanced therapy medicinal products in Europe;Cytotherapy;2023-12

4. Data-driven fair resource allocation for novel emerging epidemics: a COVID-19 Convalescent Plasma case study;INFOR: Information Systems and Operational Research;2023-10-06